GEN Exclusives

More »

GEN News Highlights

Back to Item »

BMS Pays Innate Pharma $35M Up Front for Global Rights to Clinical-Stage Cancer mAb

Phase I AML candidate IPH 2102 works by blocking KIR on natural killer cells.

Forward this item to a colleague:


(Separate multiple addresses by commas)


(Separate multiple addresses by commas)


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Sustainability in New Dietary Guidelines

Do you think that sustainability considerations should be incorporated into the new Dietary Guidelines for Americans?

More »